Xencor Appoints Barbara J. Klencke, M.D., to Board of Directors
19 Septembre 2023 - 10:01PM
Business Wire
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical
company developing engineered antibodies and cytokines for the
treatment of cancer and autoimmune diseases, today announced the
appointment of Barbara J. Klencke, M.D., to its board of directors.
Dr. Klencke has more than 20 years of biopharmaceutical product
development experience, and she most recently served as chief
medical officer and chief development officer at Sierra Oncology
through mid-2023. While at Sierra Oncology, she built a highly
effective clinical development organization and led its strategy
and execution, culminating in the approval of Ojjaara™ for
myelofibrosis following the company’s acquisition by GSK.
“Dr. Klencke is a world-class, patient-focused research and
development expert, who has a successful track record in
development and early commercialization of several medicines
approved for the treatment of patients with cancer. We look forward
to benefitting from the tremendous amount of experience and
additional perspective she brings to Xencor, as we advance our
pipeline of XmAb® drug candidates across multiple solid tumor
types,” said Bassil Dahiyat, Ph.D., president and chief executive
officer at Xencor.
Before joining Sierra Oncology in 2015, Dr. Klencke served as
senior vice president of global development at Onyx
Pharmaceuticals, where she led development and execution for Onyx’s
pipeline programs, including the approval of Kyprolis® for multiple
myeloma, through the company’s acquisition by Amgen. Between 2003
and 2011, she served as a group medical director at Genentech,
where she led product development strategies for several early- and
late-stage oncology programs, including Kadcyla®, Avastin® and
Tarceva®. Earlier in her career, Dr. Klencke was an assistant
clinical professor of medicine at the University of California, San
Francisco (UCSF), where she focused on clinical research in
oncology. Dr. Klencke also serves on the Boards of Directors of
eFFECTOR Therapeutics, Immune-Onc Therapeutics and TScan
Therapeutics. Dr. Klencke earned a Bachelor of Science degree from
Indiana University and an M.D. from the University of California,
Davis. She completed her internal medicine residency and a
hematology and oncology fellowship at UCSF.
Ojjaara™ is a trademark of the GSK group of companies. Kyprolis®
is a registered trademark of Onyx Pharmaceuticals, Inc. Kadcyla®,
Avastin® and Tarceva® are registered trademarks of Genentech,
Inc.
About Xencor
Xencor is a clinical-stage biopharmaceutical company developing
engineered antibodies and cytokines for the treatment of patients
with cancer and autoimmune diseases. More than 20 candidates
engineered with Xencor's XmAb® technology are in clinical
development, and three XmAb medicines are marketed by partners.
Xencor's XmAb engineering technology enables small changes to a
protein's structure that result in new mechanisms of therapeutic
action. For more information, please visit www.xencor.com.
Forward-Looking Statements
Certain statements contained in this press release may
constitute forward-looking statements within the meaning of
applicable securities laws. Forward-looking statements include
statements that are not purely statements of historical fact, and
can generally be identified by the use of words such as
“potential,” “can,” “will,” “plan,” “may,” “could,” “would,”
“expect,” “anticipate,” “seek,” “look forward,” “believe,”
“committed,” “investigational,” and similar terms, or by express or
implied discussions relating to Xencor’s business, including, but
not limited to the quotations from Xencor's president and chief
executive officer, and other statements that are not purely
statements of historical fact. Such statements are made on the
basis of the current beliefs, expectations, and assumptions of the
management of Xencor and are subject to significant known and
unknown risks, uncertainties and other factors that may cause
actual results, performance or achievements and the timing of
events to be materially different from those implied by such
statements, and therefore these statements should not be read as
guarantees of future performance or results. Such risks include,
without limitation, the risks associated with the process of
discovering, developing, manufacturing and commercializing drugs
that are safe and effective for use as human therapeutics and other
risks, including the ability of publicly disclosed preliminary
clinical trial data to support continued clinical development and
regulatory approval for specific treatments, in each case as
described in Xencor's public securities filings. For a discussion
of these and other factors, please refer to Xencor's annual report
on Form 10-K for the year ended December 31, 2022 as well as
Xencor's subsequent filings with the Securities and Exchange
Commission. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof.
This caution is made under the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995, as amended to
date. All forward-looking statements are qualified in their
entirety by this cautionary statement and Xencor undertakes no
obligation to revise or update this press release to reflect events
or circumstances after the date hereof, except as required by
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230919254402/en/
Charles Liles cliles@xencor.com 626-737-8118
For Media: Jason I. Spark Evoke Canale
jason.spark@evokegroup.com 619-849-6005
Xencor (NASDAQ:XNCR)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Xencor (NASDAQ:XNCR)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024